HEMISPHERX BIOPHARMA INC (HEB) Stock News
NYSEARCA:HEB - NYSE Arca -
HEB Latest News, Press Relases and Analysis
Hemispherx Bio changes name to AIM Immunotech
Hemispherx Biopharma (NYSEMKT:HEB) has changed its name and ticker symbol to AIM ImmunoTech Inc. and "AIM", respectively, effective September 3, 2019.
The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 13) GENMAB A/S/S ADR (NASDAQ...
The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ...
Maxim Group Thinks Hemispherx Biopharma Inc’s Stock is Going to Recover
Maxim Group analyst Jason McCarthy maintained a Buy rating on Hemispherx Biopharma Inc (HEB) yesterday and set a price target of $8. The company's shares
Maxim Group Thinks Hemispherx Biopharma Inc’s Stock is Going to Recover
Maxim Group analyst Jason McCarthy maintained a Buy rating on Hemispherx Biopharma Inc (HEB – Research Report) yesterday and set a price target of $8. The company’s shares opened today at $2.19, close to its 52-week low of $2. McCarthy commented: “Hemispherx Biopharma announced positive safety and survival results from its Phase 1/2 trial evaluating
The Chief Science of Hemispherx Biopharma Inc (NYSE MKT: HEB) is Buying Shares
Today, the Chief Science of Hemispherx Biopharma Inc (HEB – Research Report), David Strayer, bought shares of HEB for $9,998. Following this transaction David Strayer’s holding in the company was increased by 84.42% to a total of $21.57K. In addition to David Strayer, 5 other HEB executives reported Buy trades in the last month. See
The Sr. VP of Operations of Hemispherx Biopharma Inc (NYSE MKT: HEB) is Buying Shares
Today, the Sr. VP of Operations of Hemispherx Biopharma Inc (HEB – Research Report), Wayne Springate, bought shares of HEB for $21K. This recent transaction increases Wayne Springate’s holding in the company by 150.56% to a total of $36.08K. In addition to Wayne Springate, 2 other HEB executives reported Buy trades in the last month.
A Director at Hemispherx Biopharma Inc (NYSE MKT: HEB) is Buying Shares
Today, a Director at Hemispherx Biopharma Inc (HEB – Research Report), William M. Mitchell, bought shares of HEB for $39K. Following this transaction William M. Mitchell’s holding in the company was increased by 86.7% to a total of $86.69K. In addition to William M. Mitchell, one other HEB executive reported Buy trades in the last
The Chief Science of Hemispherx Biopharma Inc (HEB) is Buying Shares
Today, the Chief Science of Hemispherx Biopharma Inc (HEB), David Strayer, bought shares of HEB for $9,998. Following this transaction David Strayer's
The Sr. VP of Operations of Hemispherx Biopharma Inc (HEB) is Buying Shares
Today, the Sr. VP of Operations of Hemispherx Biopharma Inc (HEB), Wayne Springate, bought shares of HEB for $21K. This recent transaction increases Wayne
A Director at Hemispherx Biopharma Inc (HEB) is Buying Shares
Today, a Director at Hemispherx Biopharma Inc (HEB), William M. Mitchell, bought shares of HEB for $39K. Following this transaction William M. Mitchell's
The Exec. Vice Chairman of Hemispherx Biopharma Inc (HEB) is Buying Shares
Today, the Exec. Vice Chairman of Hemispherx Biopharma Inc (HEB), Thomas Equels, bought shares of HEB for $118.5K. Following this transaction Thomas
The Exec. Vice Chairman of Hemispherx Biopharma Inc (NYSE MKT: HEB) is Buying Shares
Today, the Exec. Vice Chairman of Hemispherx Biopharma Inc (HEB – Research Report), Thomas Equels, bought shares of HEB for $118.5K. Following this transaction Thomas Equels’ holding in the company was increased by 2.16% to a total of $5.62 million. See today’s analyst top recommended stocks >> Currently, Hemispherx Biopharma Inc has an average volume